https://doi.org/10.4081/ejtm.2026.15475
27 | Polymeric nanoparticles as a favorable delivery system to enhance the anti-inflammatory action of n-palmitoylethanolamide, an endocannabinoid-like molecule
E. Maretti1, C. Rustichelli1, B. Recchia1, G. Battaglia, E. de Nicola1, C. Fuoco2, A. Votta3, C. Gargioli2, E. Ferraro3, E. Leo1, Susanna Molinari1 | 1Dept. of Life Sciences, University of Modena and Reggio Emilia, Modena, Italy; 2Dept. Of Biology, Tor Vergata Rome University, Rome, Italy; 3Dept. of Biology, University of Pisa, Pisa, Italy.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: 3 April 2026
Chronic low-grade inflammation is linked to age-related muscle loss (sarcopenia), highlighting the potential of daily anti-inflammatory strategies. A growing body of evidence suggests that N-palmitoylethanolamide (PEA), a natural endocannabinoid-like compound with anti-inflammatory properties, could represent a safe therapeutic option to counteract sarcopenia. However, the low solubility of PEA significantly limits its systemic bioavailability. To overcome this limitation, our work was aimed to develop a nanoparticle-based delivery system intended to enhance its systemic availability. We compared two nanoparticle formulations: solid lipid nanoparticles (SLNs) and poly-(lactic-co-glycolic acid) (PLGA) polymeric nanoparticles. These delivery systems were evaluated in terms of cellular uptake, cytotoxicity, and impact on myogenic differentiation. Our results indicate that PLGA nanoparticles exhibit superior cellular internalization compared to SLNs, display lower cytotoxicity, and do not substantially interfere with the myogenic differentiation process in cell culture. Furthermore, PEA encapsulated within PLGA nanoparticles effectively activated its canonical target, peroxisome proliferator-activated receptor alpha (PPAR-α), and protected muscle cells from lipopolysaccharide (LPS)-induced cytotoxicity in vitro. These findings represent a critical step toward the preclinical evaluation of PEA as a potential therapeutic agent for counteracting sarcopenia, using murine models of age-related muscle wasting.
Funding: European Union Next Generation EU” n. P2022LSW98 (PRIN-PNRR 2022 from Italian "Ministero dell'Università e della Ricerca".
Downloads
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.